

**ESTRADIOL 1mg / PROGESTERONE 100mg capsules (Bijuve®)  
for oestrogen deficiency symptoms in postmenopausal women**

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of ESTRADIOL / PROGESTERONE capsules (Bijuve®) for oestrogen deficiency symptoms in postmenopausal women.**

**GREY**

Estradiol 1mg / progesterone 100mg (Bijuve®) is indicated for use as continuous combined hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses.<sup>[1]</sup>

This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.

In the meantime, treatment of oestrogen deficiency symptoms in postmenopausal women should continue to follow national guidance and local formulary choices:

- > NICE Guideline [NG23]: [Menopause: diagnosis and management](#), updated 05 December 2019
- > NICE Clinical Knowledge Summary (CKS): [Hormone replacement therapy \(HRT\)](#), updated November 2020
- > Pan Mersey APC Formulary: [Oestrogens and HRT](#)

**References**

1. Theramex UK Limited. Summary of Product Characteristics; [BIJUVE 1mg/100mg Capsules, soft](#), 26 February 2021. Accessed online 11 October 2021.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.